Maegim

Stock search

Search by company name, 6-digit code, or Korean initials (e.g. ㅅㅅㅈㅈ)

☆한국어

Aprogen, Inc

에이프로젠007460KOSPISector: Pharma & Biotech
₩2,1603.85%Market cap ₩53.6BAs of Sep 4, 2026 close · updated once daily
Market cap
₩53.6B
#696 in KOSPI
Loss
PER not computable
0.34x
Sector median 1.59x
0.0%
Sector median 0.0%
C
Grade C40.2 ptsBottom 30% of 2,522 graded stocksMethodology v2.0
Financial strength
28.9/100
Growth momentum
46.0/100
Price attractiveness
49.4/100
Shareholder Return
37.5/100

As of Sep 4, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

How to read this grade
SABCCurrentDF

Toward S means a higher total-score band; toward F, a lower band. Badges are distinguished by ink intensity and shape (fill, outline, dashed) — never by hue.

Maegim maps a total score — built from sector-relative percentile scoring — onto fixed, predefined thresholds to assign one of six bands, S to F. This stock is scored by the same formula as all 2,522 graded stocks and is currently in band C with a total score of 40.2 points.

How grades are computed →What grades do and don’t mean →What the grade does not reflect →

Position within sector

Mechanically selected indicators in the top or bottom 30% of sector percentiles · among 250 stocks in Pharma & Biotech

1-year closing price

Loading closing price history…
 
Low ₩2,060High ₩15,746
Latest close
Price change by period
1W
9.60%
1M
16.60%
3M
34.90%
1Y
82.20%

Adjusted for 1 price-basis change(s) such as stock splits or reverse splits during the period.

As of the Sep 4, 2026 close · updated once daily · a factual record computed from closing prices only; dividends are not included, and this is not a buy or sell signal.

1

Financial strength

28.9/100
How much debt does it carry relative to equity?
56.4%
Sector median 51.6%
Sector lowhighBottom 46% in sector
Can it cover what's due within a year?
97.2%
Sector median 191.7%
Sector lowhighBottom 22.9% in sector
How much of revenue becomes profit?
-81.0%
Sector median -2.4%
Sector lowhighBottom 28.1% in sector
How much did it earn on its own capital?
-44.3%
Sector median -4.5%
Sector lowhighBottom 18.4% in sector

Source filing: annual report (consolidated) — view original ↗

2

Growth momentum

46.0/100
How much did revenue grow in a year?
-21.4%
Sector median 6.4%
Sector lowhighBottom 11.1% in sector
Has it grown steadily over three years?
14.6%
Sector median 4.9%
Sector lowhighTop 21.2% in sector
Did core profits grow in a year?
-10.1%
Sector median 3.6%
Sector lowhighBottom 36.7% in sector
Are core profits higher than three years ago?
19.9%
Sector median 3.5%
Sector lowhighTop 42.7% in sector

Financial trend

Revenue

Growth & margin

Revenue growth Operating margin

Year over year — alongside the sector median

This stock Sector median

A factual chart of confirmed annual results from annual reports — the same source as the grading indicators. Not a buy or sell signal.

Source filing: annual report (consolidated) — view original ↗

3

Price attractiveness

49.4/100
Is the price expensive relative to earnings?
Loss-making (P/E not computable)
Sector median P/E of profitable peers 15.7x · 58% loss-making
Sector lowhighBottom 1.4% in sector
Is the price expensive relative to book value?
0.34x
Sector median 1.59x
Sector lowhighTop 2.6% in sector

Valuation uses the Sep 4, 2026 close and market cap

4

Shareholder Return

Single-indicator axis37.5/100
Does the company actually pay dividends?
0.0%
Sector median 0.0%
Sector lowhighBottom 37.5% in sector

Dividends & treasury shares

Treasury shares (FY2025)
20,758,761 shares (6.3% of shares issued)

Source: annual report (DART) — dividend allocation & total shares

Source filing: annual report (consolidated) — view original ↗

Financial checklist

Based on the FY2025 annual report · year-over-year comparison · determined on Sep 7, 2026

Of 9 items: 1 met · 8 not met · 0 not computable

Not metMetNot computable

Positive net income
Whether net income (attributable to owners where available) is above zero.
Not met
-₩70.2B
Positive operating cash flow
Whether cash flow from operations is above zero.
Not met
-₩32.7B
Return on assets up
Whether net income over beginning total assets rose from the prior year.
Not met
-9.8% → -11.5%
Operating cash flow exceeds net income
Whether operating cash flow is greater than net income.
Met
-₩32.7B vs -₩70.2B
Liabilities-to-assets ratio down
Whether total liabilities as a share of total assets fell from the prior year.
Not met
27.9% → 36.1%
Current ratio up
Whether current assets over current liabilities rose from the prior year.
Not met
118.9% → 97.2%
Shares outstanding not increased
Whether common shares issued did not increase from the prior year. Increases from bonus issues and stock dividends are also counted.
Not met
304,124,494 → 329,305,030
Operating margin up
Whether operating income over revenue rose from the prior year.
Not met
-57.8% → -81.0%
Asset turnover up
Whether revenue over beginning total assets rose from the prior year.
Not met
0.25x → 0.19x

A record of facts determined by fixed rules from the financial statements in the latest annual report. Not used in grading, and not a buy or sell signal. Source filing: annual report (consolidated) — view original ↗

Grade change history

Jul 23, 2026C

Methodology version change (v2.0 applied)

Jul 15, 2026CVersion v1

First calculation

Grade changes are a factual record produced from public data by a fixed formula; they do not signal future changes.

Disclosure & financial badges

Factual records determined from public filings and periodic reports by fixed rules — not buy/sell signals.

Negative-evidence group (dilution, loss, dispute)Mixed interpretationPositive-evidence group (shareholder return)Dots classify the disclosure type by the direction of research evidence — not an assessment or investment judgment about this company.

Disclosure event history

Private CB/BW issuance resolutions (past 36 months)

7 private-placement convertible bond (CB) / bond-with-warrants (BW) issuance resolutions were disclosed in the past 36 months (latest filing 2026-09-03). View filing ↗

CB with conversion-price adjustment clause (past 36 months)

7 convertible bond (CB) issuance resolutions including a downward conversion-price adjustment (refixing) clause were disclosed in the past 36 months (latest filing 2026-09-03). View filing ↗

Financial fact combinations

Operating losses for 3 consecutive fiscal years

Recorded operating losses in three consecutive fiscal years, FY2023–FY2025 (per annual reports).

Determined as of 2026-09-07

Recent filings for this stock

Last 120 days · monitored filing types only
Convertible bond issuanceSep 3, 2026Source ↗
Periodic report filedAug 14, 2026Source ↗
Convertible bond issuanceAug 10, 2026Source ↗
Convertible bond issuanceAug 10, 2026Source ↗
Convertible bond issuanceJul 13, 2026Source ↗

View in the filings calendar →